Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 4/20 | 0.73 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.73 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.73 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tasosartan SCHEMBL49627 | 0.84 | AGTR1 (1.00) | AGTR1TBXA2RAGTR2PDE3A | |
| SCHEMBL13262874 | 0.69 | AGTR1 (0.55) | AGTR1AGTR2 | |
| SCHEMBL15336224 | 0.68 | AGTR1 (0.72) | AGTR1AGTR2 | |
| SCHEMBL7429405 | 0.68 | AGTR1 (0.61) | AGTR1TBXA2RAGTR2PDE3A | |
| SCHEMBL14255053 | 0.68 | AGTR1 (0.67) | AGTR1AGTR2 | |
| SCHEMBL8293198 | 0.67 | TP53 (0.71) | AGTR1AGTR2PDE3A | |
| Tasosartan SCHEMBL49626 | 0.67 | AGTR1 (0.71) | AGTR1TBXA2RAGTR2PDE3A | |
| SCHEMBL29486800 | 0.67 | AGTR1 (1.00) | AGTR1AGTR2 | |
| SCHEMBL17015144 | 0.67 | AGTR1 (0.90) | AGTR1AGTR2PDE3ACYP3A4MAPK1 | |
| SCHEMBL12879309 | 0.66 | AGTR1 (0.70) | AGTR1AGTR2PDE3ACYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150098993-A1 | COMPOSITIONS, PROCESS OF PREPARATION OF SAID COMPOSITIONS AND METHOD OF TREATING INFLAMMATORY DISEASES | CELLWORKS GROUP, INC. | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150098993-A1 | COMPOSITIONS, PROCESS OF PREPARATION OF SAID COMPOSITIONS AND METHOD OF TREATING INFLAMMATORY DISEASES | TNF, C5, IL5 | AGTR1 2464/4885TBXA2R 499/4885AGTR2 2567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.